Abstract：
Menopausal symptoms can impair the life of women at the peak of their career and family life. At the present time, the most effective treatment for these manifestations is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases in itself does not exclude the possibility of prescribing MHT to relieve menopausal symptoms and improve quality of life. However, often an obstacle to the use of this type of hormone therapy is the fear of physicians to do more harm to patients than good. Caution is especially important when it comes to women with concurrent diseases. Moreover, it should be recognized that there is a shortage of high-quality research on the safety of MHT for underlying chronic non-infectious diseases and common comorbidities. The presented consensus analyzed all currently available data from clinical trials of various designs and created a set of criteria for the appropriateness of prescribing MHT to women with concomitant cardiovascular and metabolic diseases. Based on the presented document, physicians of various specialties who advise menopausal women will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and reasonably prescribe MHT in real-life practice.
摘要：
更年期症状会损害女性在职业生涯和家庭生活高峰期的生活。目前,这些症状最有效的治疗方法是更年期激素治疗（MHT）。心血管和代谢疾病的存在本身并不排除处方MHT以缓解更年期症状并改善生活质量的可能性。然而,使用这种激素疗法的一个障碍通常是医生害怕对患者造成更大的伤害。当涉及到患有并发疾病的女性时，谨慎尤其重要。此外，应该认识到，缺乏关于MHT对潜在慢性非感染性疾病和常见合并症的安全性的高质量研究。提出的共识分析了来自各种设计的临床试验的所有当前可用数据，并为患有心血管和代谢疾病的女性开具MHT的适当性制定了一套标准。根据提交的文件，为更年期妇女提供建议的各种专业的医生将获得一种可访问的算法，该算法将使他们能够避免潜在的危险情况，并在现实生活中合理地规定MHT。
